SUPERNUS PHARMACEUTICALS, INC. 8-K

What Happened

• Supernus Pharmaceuticals, Inc. held its annual meeting of stockholders on June 18, 2026 and filed an 8‑K reporting the voting results. As of the close of business on April 29, 2026, 58,039,721 shares of common stock were outstanding and entitled to vote. The company filed the related definitive proxy statement on April 30, 2026.
• Stockholders voted on four items: election of two Class I directors (terms through the 2029 annual meeting), a non‑binding advisory vote on executive compensation, ratification of KPMG LLP as independent auditor for fiscal 2026, and an amendment to increase the share reserve under the 2021 Equity Incentive Plan. Vote tallies were reported as follows:
  • Frederick M. Hudson — For: 45,058,634; Withheld: 2,177,068; Broker non‑votes: 3,073,181.
  • Charles W. Newhall, III — For: 41,743,154; Withheld: 5,492,548; Broker non‑votes: 3,073,181.
  • Say‑on‑pay (non‑binding) — For: 45,552,633; Against: 1,675,355; Abstain: 7,714; Broker non‑votes: 3,073,181.
  • Ratification of KPMG LLP — For: 49,882,228; Against: 417,336; Abstain: 9,319 (no broker non‑votes).
  • Amendment to 2021 Equity Incentive Plan — For: 41,925,692; Against: 5,302,088; Abstain: 7,922; Broker non‑votes: 3,073,181.

Key Details

• Shares outstanding and entitled to vote: 58,039,721 (as of April 29, 2026).
• Annual meeting date: June 18, 2026; proxy statement filed April 30, 2026.
• Auditor ratified: KPMG LLP received ~49.9 million votes in favor, with ~417k against.
• Say‑on‑pay: advisory approval received (about 45.6 million for vs 1.68 million against).

Why It Matters

• Governance continuity: the reported votes determine the company’s board composition (Class I directors’ terms through 2029) and keep existing auditor engagement in place, which affects oversight and financial reporting continuity.
• Executive pay and equity program: the non‑binding say‑on‑pay vote indicates shareholder sentiment on executive compensation, while approval of the equity plan amendment (vote in favor) expands the shares available for awards—important for employee incentives and potential dilution.
• For investors: these outcomes affect corporate governance, oversight and potential share dilution; they are informational signals about shareholder support for management and compensation policies.